Production (Stage)
Zevra Therapeutics, Inc.
ZVRA
$8.65
$0.080.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.40M | 12.04M | 3.70M | 4.45M | 3.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.40M | 12.04M | 3.70M | 4.45M | 3.43M |
| Cost of Revenue | 1.35M | 1.37M | 2.30M | 3.57M | 175.00K |
| Gross Profit | 19.06M | 10.68M | 1.39M | 876.00K | 3.25M |
| SG&A Expenses | 19.55M | 16.18M | 16.21M | 12.60M | 9.93M |
| Depreciation & Amortization | 1.62M | 1.62M | 1.55M | 1.55M | 1.53M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.76M | 27.46M | 31.00M | 28.24M | 23.91M |
| Operating Income | -5.36M | -15.42M | -27.31M | -23.80M | -20.49M |
| Income Before Tax | -1.92M | -20.37M | -33.23M | -19.86M | -16.69M |
| Income Tax Expenses | 1.18M | 15.37M | -- | 70.00K | -70.00K |
| Earnings from Continuing Operations | -3.10M | -35.74M | -33.23M | -19.93M | -16.62M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.10M | -35.74M | -33.23M | -19.93M | -16.62M |
| EBIT | -5.36M | -15.42M | -27.31M | -23.80M | -20.49M |
| EBITDA | -3.71M | -13.77M | -25.69M | -22.23M | -18.92M |
| EPS Basic | -0.06 | -0.67 | -0.70 | -0.48 | -0.40 |
| Normalized Basic EPS | -0.02 | -0.24 | -0.44 | -0.30 | -0.25 |
| EPS Diluted | -0.06 | -0.67 | -0.70 | -0.48 | -0.40 |
| Normalized Diluted EPS | -0.02 | -0.24 | -0.44 | -0.30 | -0.25 |
| Average Basic Shares Outstanding | 54.10M | 53.47M | 47.81M | 41.90M | 41.78M |
| Average Diluted Shares Outstanding | 54.10M | 53.47M | 47.81M | 41.90M | 41.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |